{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Ffindmyvaccine.simplecast.com%2Fepisodes%2Fcovidriskassessments-ymvd3TfE","width":444,"version":"1.0","type":"rich","title":"Dr.Zain Chagla and Dr.Srinivas Murthy: Do We Need to Rethink Who's High Risk for the COVID Booster?","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/da812cf9-ccc4-4bdc-96e2-1d3f346ea466/booster.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"▶️▶️ Higher risk patients today see a combination of more transmissible COVID variants, and vaccines that may have waning effectiveness.\n\nBut when we think of high-risk patients and clinically vulnerable patients, we often think about the IC patient population. How about if you’re obesity or have diabetes, heart failure, high cholesterol, hypertension, or COPD? How about those with specific cognitive or physical disabilities? What is high risk beyond the immunocompromised patient population?\n\nWe're joined by two Infectious disease experts who deliver a real-time masterclass on assessing COVID risk in your patients and connect the emerging data around the 1st and 2nd COVID-19 vaccine boosters.\n\n📰 📺 The famous Ask the Expert questions in this episode explore specific risk factors beyond age and how to effectively translate and frame the booster conversation on the frontline with your patient. How do you screen and communicate on the frontline? And how do we look at NACI guidance on boosters when compared to JCVI's recommendations for the Fall?\n\nDr.Chagla and Dr.Murthy also compete to see who can number crunch a risk assessment in real time the fastest. \n\nEPISODE LEARNING OBJECTIVES: \no Explore the current understanding and definition of high-risk patient populations and how to stratify risk in the context of progression to severe COVID-19 disease based on comorbidities \no Demonstrate how frontline healthcare providers can effectively screen patients with comorbidities for COVID-19 booster doses \no Describe how to effectively frame communication of COVID-19 booster vaccines in the context of real-world patient clinical questions"}